NASH 06/2021 Analysis of non-invasive biomarker tests in the Phase 2 FASCINATE-1 study of FASN inhibitor TVB-2640 EASL International Liver Congress Graviton Love9
NASH 11/2020 Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH AASLD Graviton Love9
NASH 08/2020 Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH EASL International Liver Congress Graviton Love9
NASH 08/2020 The FASN inhibitor TVB-2640 is efficacious in a new 3D human liver microtissue model of NASH EASL International Liver Congress Graviton Love9
NASH 07/2020 Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities Hepatology 2020 Graviton Love9
NASH 11/2018 Fibroblast Growth Factor-21 and its Relationship to Human Liver Fat Synthesis; Impact of a New Therapeutic Agent ObesityWeek Graviton Love8
NASH 01/2018 Progressive Reductions in Hepatic DNL with Increasing Doses of TVB-2640, a First-in-Class Pharmacologic Inhibitor of FASN Keystone Symposium on Organ Crosstalk in Obesity and NAFLD Graviton Love6
NASH 10/2017 Pharmacologic Inhibition of FASN Reverses Diet-Induced Steatohepatitis in Mice and Inhibits Lipogenesis in Humans. AASLD Graviton Love6